Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Guggenheim Healthcare Talks Radiopharmaceuticals Day

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

43.67 USD

Average target price

53.19 USD

Spread / Average Target

+21.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-14.18%	88.52B
ELI LILLY AND COMPANY	+32.88%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.48%	358B
MERCK & CO., INC.	+19.30%	328B
ABBVIE INC.	+3.61%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.57%	165B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:42:43 2024-05-09 pm EDT			5-day change	1st Jan Change
44.16 ^USD	+1.13%		+0.77%	-14.18%

11:25am	India's Alembic Pharma posts higher Q4 profit on strong N.America sales	RE
May. 07	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	MT

India's Alembic Pharma posts higher Q4 profit on strong N.America sales	05:25am	RE
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	May. 06	MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	May. 06	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	May. 06	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	May. 06	CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	May. 06	CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer	May. 06	CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	May. 01	MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	Apr. 30
A flurry of corporate results ahead of the Fed's rate decision	Apr. 30
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	Apr. 30
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	Apr. 30	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	Apr. 29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	Apr. 29	MT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	Apr. 29	CI
S&P 500 Q1 earnings estimated growth improves; stocks up for week	Apr. 26	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	Apr. 26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	Apr. 26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	Apr. 26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	Apr. 26	MT